Clinical trials: Haematological Malignancy, active
Haematological Cancer
Adapted Boxing and Photography in Haematology: Body Image and Self-Esteem
Although the benefits of adapted physical activity (APA) are well documented in the scientific literature, few studies have specifically examined the impact of adapted boxing on body image and self-esteem in patients with…
- Trial name
- BOXITUDE (NCT07888959)
- Testing
- adapted boxing session
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Lymphocytic Leukemia, Haematological Malignancy
variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
This study will use surveys within primary and secondary care to explore referral patterns and healthcare professional (HCP) decision-making and advice for haematological malignancies, identify inequalities, and establish best…
- Trial name
- TITLE CLL (NCT07463976)
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Solid Cancer, Haematological Malignancies
Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)
This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral…
- Trial name
- NCT06797037
- Testing
- Decentralised Pathway Coordinated by the Advanced Practice Nurse
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Claudius Regaud
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Solid Tumour
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation.
- Trial name
- DETERMINE (NCT05722886)
- Testing
- Alectinib, Atezolizumab, Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 825 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Acute Myeloid Leukemia
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
- Conditions
- Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT04068597
- Testing
- CCS1477, Pomalidomide, Dexamethasone
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 250 people
- Sponsor
- CellCentric Ltd.
Fungal Infection, Haematological Malignancy
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally…
- Conditions
- Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
- Trial name
- PRAGMATIC (NCT06510699)
- Testing
- genotype-directed dosing with dosing software based on therapeutic drug monitoring
- Where
- 7 sites in United States, Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Malignancy
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called…
- Conditions
- Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders
- Trial name
- DETERMINE (NCT05770544)
- Testing
- Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Thrombocytopaenia, Haematological Malignancies
Clinical Efficacy of Platelet Transfusion
The aim of this study is to analyze the effect of the storage time of platelet concentrates on the occurrence of bleeding events during prophylactic platelet transfusions in patients with hematological malignancies.
- Trial name
- ECLAT (NCT06805097)
- Testing
- Self-assessment of bleeding events
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Sarcomas, Haematological Malignancies
Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors
The study aims to test for the presence or absence of primary tumor-specific tumor markers in ovarian tissue. Therefore, there will be a first phase in which pathology-specific markers will be identified in the patients'…
- Trial name
- NCT06829654
- Testing
- Step 1, Step 2, Step 3
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy
Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital
Patients undergoing particular intensive and (sub)myeloablative chemotherapy regimens with subsequent autologous stem cell transplant currently have a relatively low rate of therapy-related complications, both infectious and…
- Trial name
- AMICO (NCT06814405)
- Testing
- Home patient management, Hospital patient management
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy, Febrile Neutropenia
Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With Febrile Neutropenia
The goal of this observational study is to assess if the molecular diagnostic tool BioFire FilmArray BCID2 is more useful for the microbiological diagnosis of bloodstream infections in hematological patients with febrile…
- Conditions
- Haematological Malignancy, Febrile Neutropenia, Blood Stream Infection
- Trial name
- ONFIRE (NCT06787326)
- Where
- Spain
- Volunteers
- 228 people
- Sponsor
- Hospital Universitari de Bellvitge
Haematological Cancer, Healthy
Pulsed Electromagnetic Fields in Preventing Physical Deconditioning in Patients Undergoing Prolonged Hospitalization
The goal of this clinical trial is to examine if pulsed electromagnetic fields (PEMF) can prevent or decrease physical deconditioning associated with prolonged hospitalisation and immobility of haematology patients.
- Trial name
- PEMF (NCT06744764)
- Testing
- PEMF (1mT), PEMF (0mT)
- Where
- 2 sites in Singapore
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Advanced Cancer, Solid Tumor
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used…
- Conditions
- Advanced Cancer, Solid Tumor, Haematological Malignancy
- Trial name
- FINPROVE (NCT05159245)
- Testing
- Alectinib, Cobimetinib, Vismodegib
- Where
- 5 sites in Finland
- Volunteers
- 250 people
- Sponsor
- Helsinki University Central Hospital
Haematological Malignancy, Hypogammaglobulinemia
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics…
- Trial name
- RATIONALISE (NCT05678621)
- Testing
- trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins
- Where
- 7 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Monash University
Solid Tumor, Unspecified, Adult, Haematological Malignancy
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic…
- Trial name
- NCT05695638
- Where
- Denmark
- Volunteers
- 3,000 people
- Sponsor
- Morten Ladekarl